LANDSVIRKJUN
14.12.2016 12:02:27 CET | Business Wire | Press release
Landsvirkjun, the National Power Company of Iceland, and Advania have signed a power purchase agreement for the supply of energy to Advania’s Fitjar data centre in the southwest of Iceland. The energy will be supplied by the end of 2016 according to the agreement, which will enable Advania to continue to expand their data center operations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161214005221/en/
Landsvirkjun will supply the energy through its current power station network. The company has supported the growth of the data center industry in recent years in Iceland by offering energy from 100% renewable resources.
Hörður Arnarson, CEO of Landsvirkjun:
"Advania is a welcome addition to Landsvirkjun’s client base. The conditions in Iceland are ideal for data center operations and Landsvirkjun has in recent years actively promoted Iceland as a preferred location for data centers. The successful growth of Advania and other data centers in Iceland is based on favourable, long-term, secure energy contracts, a competitive environment and the cooperation of stakeholders within the industry in Iceland."
Gestur G. Gestsson, CEO of Advania:
"The scope of Advania’s operations, within the data center market, has grown tremendously in recent years and large-scale projects are in the pipeline in the coming months. Access to energy is a key factor in the operation of data centers and we are therefore greatly pleased by this agreement with Landsvirkjun. We believe That Landsvirkjun will strengthen our ability to service more global clients in the future. "
Advania is a leading Nordic IT company with operations in Iceland, Sweden and Norway. The company has around 1000 employees, working from 20 different stations of operation. Advania operates the Steinhella Data Center in Hafnarfjordur and the Fitjar Data Center in Reykjanesbær. The agreement will allow the company to further grow its data center operations and add to its client base.
Landsvirkjun generates 100% of its power from renewable resources. The company owns and operates 16 power stations, including 14 hydropower stations and two geothermal stations as well as two wind turbines. Landsvirkjun is currently constructing a geothermal power station at Þeistareykir in the northeast of Iceland and is also expanding its hydropower station network in Búrfell, in the south of Iceland.
The offering of favourable long-term power purchase agreements makes Iceland a competitive location to set up data centers and the stable, cold climate of the country is particularly suitable for data center operations. Redundant submarine fibre cable system provides the reliable connectivity required by demanding international data centers.
Landsvirkjun has actively promoted Iceland to the responsible parties for determining future locations of data centers. The Company's website contains information on the benefits of Iceland in this regard:
http://www.landsvirkjun.com/datacenters
View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005221/en/
Contact:
Landsvirkjun
Magnús Þór Gylfason, +354 515 9000
Director of
Corporate Communications
Magnus.Thor.Gylfason@landsvirkjun.is
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom